home / stock / dsnky / dsnky news


DSNKY News and Press, Daiichi Sankyo Co Ltd Sponsored ADR Level 1 From 04/02/24

Stock Information

Company Name: Daiichi Sankyo Co Ltd Sponsored ADR Level 1
Stock Symbol: DSNKY
Market: OTC

Menu

DSNKY DSNKY Quote DSNKY Short DSNKY News DSNKY Articles DSNKY Message Board
Get DSNKY Alerts

News, Short Squeeze, Breakout and More Instantly...

DSNKY - FDA accepts Daiichi Sankyo-AstraZeneca's breast cancer therapy for review

2024-04-02 08:16:01 ET AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo’s ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) biologics license application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for patients with previously treated metastatic HR-posit...

DSNKY - Daiichi Sankyo-AstraZeneca gets BLA approved for lung cancer therapy in the U.S.

2024-02-19 07:36:17 ET Read the full article on Seeking Alpha For further details see: Daiichi Sankyo-AstraZeneca gets BLA approved for lung cancer therapy in the U.S.

DSNKY - Pharma giants turn to China in search of targeted cancer drugs

2024-02-04 12:00:49 ET More on AbbVie, Johnson & Johnson, etc. AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript Merck & Co., Inc. 2023 Q4 - Results - Earnings Call Presentation Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript AbbVie cit...

DSNKY - Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript

2024-02-01 21:45:05 ET Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Conference Call January 31, 2024, 02:00 AM ET Company Participants Koji Ogawa - Head of Global Corporate Planning & Management, CFO Wataru Takasaki - Head of Japan R&D Confe...

DSNKY - Merck posts Q4 beat as Keytruda outperforms

2024-02-01 07:28:53 ET More on Merck Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings Merck: Set To Keep Soaring Post Q4 Release Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides) Merck Non-GAAP EPS of $0.03 beats...

DSNKY - Karuna's KarXT tops Evaluate's most anticipated drug list

2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...

DSNKY - AstraZeneca/ Daiichi win FDA priority review for Enhertu label expansion

2024-01-29 06:46:23 ET More on AstraZeneca Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AstraZeneca launches asthma re...

DSNKY - Gilead in selloff after late-stage setback for Trodelvy

2024-01-22 13:11:37 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold Biggest stock movers...

DSNKY - ClearBridge Global Growth Strategy Q4 2023 Portfolio Manager Commentary

2024-01-21 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Global growth equities...

DSNKY - Pfizer faces setback in Enhertu patent dispute with Daiichi

2024-01-17 07:08:09 ET More on Pfizer Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Pfizer: 50% Down From The Highs, Generous Dividend, And Robust Balance Sheet First RSV...

Previous 10 Next 10